The FDA has approved baxdrostat (Baxfendy – AstraZeneca), an oral aldosterone synthase inhibitor, for add-on treatment of hypertension in adults whose blood pressure is not adequately controlled on other drugs. Baxdrostat is the first aldosterone synthase inhibitor to become available in the US.
STANDARD TREATMENT — Hypertension is considered resistant when it remains uncontrolled despite optimal treatment with three or more drugs, including a diuretic; a typical three-drug regimen consists of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), a calcium...
- Tradipitant (Nereus) for Motion Sickness
- Dextromethorphan/Bupropion (Auvelity) for Agitation in Alzheimer’s Dementia
- In Brief: An Expanded Indication for Teplizumab (Tzield)
- In Brief: Widaplik — Another Three-Drug Combination for Hypertension
- In Brief: Dupilumab (Dupixent) for Allergic Fungal Rhinosinusitis
- In Brief: Apixaban vs Rivaroxaban for Acute VTE
- Comparison Chart: Drugs for Motion Sickness (online only)
ISSUE
The FDA has approved an IV formulation of the epoxide antibacterial drug fosfomycin (Contepo – Meitheal) for treatment of adults with complicated urinary tract infections (cUTIs) caused by susceptible isolates of Escherichia coli or Klebsiella pneumoniae. Oral fosfomycin has been available in the US for years for treatment of uncomplicated urinary tract infections. IV fosfomycin has been available in other countries for decades.
STANDARD TREATMENT — Complicated UTIs (i.e., UTIs in men or women that extend beyond the bladder) often occur in patients with indwelling urinary catheters or anatomic or functional abnormalities of the urinary tract. They are often caused by antibiotic-resistant gram-negative bacteria such as E. coli, K. pneumoniae, Proteus mirabilis, and Pseudomonas aeruginosa. Hospitalized patients with cUTIs generally receive empiric …